<DOC>
	<DOC>NCT01959685</DOC>
	<brief_summary>To determine the tolerability and pharmacokinetics (PK) of a single dose of Androxal in healthy adult male subjects as the dose to be investigated in a thorough QT interval/corrected QT interval (QT/QTc) study.</brief_summary>
	<brief_title>A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal</brief_title>
	<detailed_description>A dose escalating study to determine the tolerability and pharmacokinetics (PK) of a supra-therapeutic dose of Androxal, up to 250 mg, in healthy adult male subjects as the dose to be investigated in a thorough QT interval/corrected QT interval (QT/QTc) study.</detailed_description>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<criteria>Speaks, reads, and understands English or Spanish and is willing and able to provide written informed consent on an institutional review board (IRB)approved form prior to the initiation of any study procedures; Male, between the ages of 1860 years; No significant abnormal findings at the screening physical examination as evaluated by the Investigator; Normal laboratory values (or abnormal but not clinically significant) at screening as determined by the Investigator; Subject is willing to remain in the clinic overnight for the Day 1 and Day 8 visits; Must be able to swallow gelatin capsules Known hypersensitivity to Clomid; Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Investigator; Subject with a significant organ abnormality or disease as determined by the Investigator; Any medical condition that would interfere with the study as determined by the Investigator; Slow cytochrome P450 2D6 (CYP2D6) metabolizer Participation in a clinical trial with investigational medication within 30 days prior to study medication administration; An acute illness within 5 days of study medication administration; Positive urine drug screen at the screening visit; A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator; History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism); History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of QTc interval prolongation; An employee or family member of an employee of the study site or the Sponsor;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>